



CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED
中國神威藥業集團有限公司
(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立之有限公司)
(股份代號: 2877)

26 April 2024

Dear registered shareholder(s),

China Shineway Pharmaceutical Group Limited (the “Company”)
- Notice of Publication of 2023 Annual Report, Circular and Proxy Form (“Current Corporate Communication”)

The English and Chinese versions of the Company’s Current Corporate Communication are available on the Company’s website at www.shineway.com.hk and on the HKEXnews website at www.hkexnews.hk or the arranged printed form(s) of Current Corporate Communication is enclosed (if applicable).

Solicitation of electronic contact details

To ensure timely receipt of the latest Corporate Communications and Actionable Corporate Communications^(Note), the Company recommends you provide your email address by scanning your personalized QR code printed on the reply form on the reverse side of this notice (the “Reply Form”). Alternatively, you may sign and return the Reply Form to the Company’s Hong Kong share registrar (the “Share Registrar”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Share Registrar, you will (i) be unable to receive any notifications regarding the publication of Corporate Communications; (ii) need to proactively check the Company’s website and the HKEXnews website to keep up with the publication of Corporate Communications; and (iii) the Company will send the Actionable Corporate Communications^(Note) in printed form in the future.

If you want to receive the Corporate Communications in printed form, please complete the enclosed Reply Form and send it to the Share Registrar or send an email to ChinaShineway.ecom@computershare.com.hk specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

-Notice of Publication of Environmental, Social and Governance Report 2023 (the “ESG Report 2023”)

We hereby notify you that the English and Chinese versions of the ESG Report 2023 are now available in the “Investor Relations” section of the Company’s website at www.shineway.com.hk and on the HKEXnews website at www.hkexnews.hk. You may access the ESG Report 2023 through the Company’s website and the HKEXnews website.

Should you have any queries relating to this letter, please contact the Share Registrar at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

Yours faithfully,
For and on behalf of
China Shineway Pharmaceutical Group Limited
Lee Bun Ching Terence
Company Secretary

Note: Actionable Corporate Communication is any corporate communication that seeks instructions from the Company’s securities holders on how they wish to exercise their rights or make an election as the Company’s securities holders.

各位登記股東：

中國神威藥業集團有限公司（「本公司」）
- 2023 年度報告、股東週年大會通函及委任代表表格（「本次公司通訊」）之發佈通知

本公司本次公司通訊的英文及中文版本已登載於本公司網站(www.shineway.com.hk)及香港交易所披露易網站(www.hkexnews.hk)，歡迎查閱，或按安排附上本次公司通訊之印刷本(如適用)。

徵集電子聯絡資料

為確保及時收到最新的公司通訊及可供採取行動的公司通訊^(附註)，本公司建議閣下透過掃描本函背頁之回條（「回條」）上列印的閣下專屬二維碼來提供閣下的電子郵件地址。或者，閣下也可以簽署回條並交回本公司的香港股份過戶登記處（「股份過戶處」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東183號合和中心17M樓。

如果本公司沒有收到閣下的有效電子郵件地址，直至股份過戶處收到閣下有效的電子郵件地址前，閣下將(i)無法收到任何有關發布公司通訊的通知；(ii)需要主動查看本公司網站和披露易網站以留意公司通訊的發布；及(iii)本公司未來將以印刷本形式發送可供採取行動的公司通訊^(附註)。

若閣下希望收取日後公司通訊之印刷本，請填妥隨附之回條或發送電子郵件至 ChinaShineway.ecom@computershare.com.hk，並註明閣下的姓名、地址以及收取公司通訊印刷本的要求。請注意，收取日後公司通訊印刷本之指示由收悉閣下指示當日起計一年內有效，此後將過期。

- 2023 環境、社會及管治報告（「2023 環境、社會及管治報告」）的刊發通知

本公司謹通知閣下，2023 環境、社會及管治報告的英文及中文版本，現已登載於本公司網站（www.shineway.com.hk）「投資者關係」一欄，以及香港交易所披露易網站（www.hkexnews.hk）。閣下可於本公司及披露易網站內閱覽 2023 環境、社會及管治報告。

如閣下對本函件有任何疑問，請於辦公時間星期一至五（香港公眾假期除外）上午 9 時正至下午 6 時正（香港時間）期間致電股份過戶處(852) 2862 8688 查詢。

代表
中國神威藥業集團有限公司
李品正
公司秘書
謹啟

2024 年 4 月 26 日

附註：可供採取行動的公司通訊指任何涉及要求本公司的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。

